Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892123 · ClinicalTrials.gov registry record · Phase 1
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 279
- Enrollment target
NCT02892123: Completed Phase 1 study, sponsored by Jazz Pharmaceuticals.
NCT02892123 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 279 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (365% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02892123, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 279 participants
- Enrollment target
Study Summary
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
Interventions
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Tucatinib
- DRUG Vinorelbine
- DRUG ZW25 (Zanidatamab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
What the finished NCT02892123 record still lists
NCT02892123 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (365% higher).
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02892123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02892123 about?
NCT02892123 is a clinical study titled "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers". This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressi...
What is the current status of trial NCT02892123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 279 participants. The study started on 2016-09-30. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT02892123?
The interventions under investigation include: Capecitabine (DRUG), Paclitaxel (DRUG), Tucatinib (DRUG), Vinorelbine (DRUG), ZW25 (Zanidatamab) (DRUG).
Who is sponsoring clinical trial NCT02892123?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02892123's enrollment target sits among peer trials
279 146th of 2000 higher than 1,855 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI